TETERBORO, N.J., Jul 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- Quest
Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of
diagnostic testing, information and services, announced today that the proposed
revisions to the 2003 Medicare payment policies under the physician fee
schedule, as currently proposed by the Centers for Medicare & Medicaid Services
(CMS), an agency within the U.S. Department of Health and Human Services, are
not expected to have a material impact on the company's financial results. The
proposed rule is subject to comment and could be modified before being issued.
About Quest Diagnostics
Quest Diagnostics Incorporated is the nation's leading provider of diagnostic
testing, information and services, providing insights that enable physicians,
hospitals, managed care organizations and other healthcare professionals to make
decisions to improve health. The company offers the broadest access to
diagnostic laboratory services through its national network of laboratories and
patient service centers. Quest Diagnostics is the leading provider of esoteric
testing, including gene-based medical testing, and empowers healthcare
organizations and clinicians with state-of-the-art connectivity solutions that
improve practice management. Additional company information can be found on the
Internet at http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking statements
involve risks and uncertainties that could cause the outcome to be materially
different. Certain of these risks and uncertainties are described in the Quest
Diagnostics Incorporated 2001 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics Incorporated
CONTACT:
Investors - Laure Park, +1-201-393-5030, or Media - Gary
Samuels, +1-201-393-5700
URL: http://www.questdiagnostics.com
Copyright (C) 2002 PR Newswire. All rights reserved.